<DOC>
	<DOCNO>NCT00637871</DOCNO>
	<brief_summary>This study look relationship dose nolvadex incidence gynaecomastia also Prostate Specific Antigen ( PSA ) inhibition co-administered Casodex . The aim study ass optimal dose nolvadex reduce breast tissue adverse effect without reduce efficacy Casodex .</brief_summary>
	<brief_title>Casodex - Nolvadex Combination</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Gynecomastia</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Subjects adenocarcinoma prostate gland evidence distant metastasis . The stage disease T1T4 , N , M0 confirm histologically cytologically Subjects need immediate hormonal therapy . PSA equal 4 ng/ml Presence gynaecomastia and/or breast pain screen visit Any previous endocrine therapy prostate cancer neoadjuvant LHRH therapy prior primary therapy curative intent . Current use , within previous 6 month , medication know high risk cause gynaecomastia . Previous mastectomy radiation chest wall</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Casodex</keyword>
	<keyword>bicalutamide</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Gynaecomastia</keyword>
	<keyword>Prostate Cancer</keyword>
</DOC>